专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

81. 发明授权

US4932934A Methods for treatment of tumors 失效
标题翻译：肿瘤治疗方法
公开(公告)号：US4932934A
公开(公告)日：1990-06-12
申请号：US236603
申请日：1988-08-24
申请人： Thomas J. Dougherty , William R. Potter , Kenneth R. Weishaupt
发明人： Thomas J. Dougherty , William R. Potter , Kenneth R. Weishaupt
IPC分类号： A61B5/00 , A61K31/40 , A61K41/00 , A61K49/00 , A61K51/00 , A61N5/06 , A61P35/00 , A61P43/00 , C07D487/22 , C07D519/00 , C09B47/00 , G02B6/04 , G02B6/26 , G02B6/42
CPC分类号： A61K31/40 , A61B5/411 , A61B5/416 , A61K41/0071 , A61N5/0601 , A61N5/062 , C07D519/00 , G02B6/262 , G02B6/4204 , A61B5/0071 , A61B5/0084 , G02B6/4298 , Y10S607/901
摘要： To obtain tumor-selective, photosensitizing drugs useful in the localization of neoplastic tissue and treatment of abnormal neoplastic tissue such as tumors, one of two methods is used. In the first method, a hydrolyzed mixture of the products of reaction of hematoporphyrin with acetic acid and sulfuric acid is cycled through a microporous membrane system to exclude low molecular weight products. In the second method, drugs are synthesized or derived from other pyrrole compounds. The drugs: (1) include two covalently bound groups, each with four rings, some of which are pyrroles such as phlorins, porphyrins, chlorins, substituted pyrroles, substituted chlorins or substituted phlorins, each group being arranged in a ring structure, connected covalently to another group and have a triplet energy state above 37.5 kilocalories per mole; (2) are soluble in water, forming an aggregate of over 10,000 molecular weight in water and have an affinity for each other compared to serum protein such that 10 to 100 percent remain self aggregated in serum protein; and (3) are lipophillic and able to disaggregate and attach to cell plasma, nuclear membrane, mitochondria, lysosomes and tissue. The drug obtained by the first method has an empirical formula of approximately C.sub.68 H.sub.70 N.sub.8 O.sub.11 or C.sub.68 H.sub.66 N.sub.8 O.sub.11 Na.sub.4. Neoplastic tissue retains the drug after it has cleared normal tissues and illumination results in necrosis. Moreover, other photosensitizing materials may be combined with a carrier that enters undesirable tissues and cells of the reticular endothelial system such as macrophages. These photosensitizing materials: (1) must have a triplet energy state above 3.5 kilocalories per mole; (2) cannot be easily oxidized; and (3) not physically quench any required energy state. Preferably, this photosensitizing material should be lipophilic.
摘要翻译：为了获得肿瘤选择性的光敏药物，可用于肿瘤组织的定位和治疗异常肿瘤组织如肿瘤，使用两种方法之一。在第一种方法中，血卟啉与乙酸和硫酸的反应产物的水解混合物循环通过微孔膜系统以排除低分子量产物。在第二种方法中，合成或衍生自其他吡咯化合物的药物。药物：（1）包括两个共价结合的基团，每个具有四个环，其中一些是吡咯，例如卟啉，卟啉，二氢卟酚，取代的吡咯，取代的二氢卟酚或取代的藜芦烯，每个组排列成环结构，共价连接到另一组，并具有高于每摩尔37.5千卡的三线态能量状态; （2）可溶于水，与血清蛋白质相比，在水中形成了超过10,000分子量的聚集体，并且与血清蛋白质具有亲和力，使得10％至100％在血清蛋白中保持自我聚集; 和（3）是脂肪性的并且能够分解并附着于细胞血浆，核膜，线粒体，溶酶体和组织。通过第一种方法获得的药物具有约C68H70N8O11或C68H66N8O11Na4的经验式。肿瘤组织清除正常组织后保留药物，照明会导致坏死。此外，其它光敏材料可以与进入网状内皮系统的不希望的组织和细胞如巨噬细胞的载体组合。这些光敏材料：（1）必须具有每千克3.5千卡以上的三线态能量状态; （2）不易氧化; 和（3）不能物理地淬灭任何所需的能量状态。优选地，该光敏材料应该是亲脂的。

82. 发明授权

US4889129A Apparatus for treatment of tumors 失效
标题翻译：用于治疗肿瘤的装置
公开(公告)号：US4889129A
公开(公告)日：1989-12-26
申请号：US243163
申请日：1988-09-08
申请人： Thomas J. Dougherty , William R. Potter , Kenneth R. Weishaupt
发明人： Thomas J. Dougherty , William R. Potter , Kenneth R. Weishaupt
IPC分类号： A61B5/00 , A61K31/40 , A61K41/00 , A61K49/00 , A61K51/00 , A61N5/06 , A61P35/00 , A61P43/00 , C07D487/22 , C07D519/00 , C09B47/00 , G02B6/04 , G02B6/26 , G02B6/42
CPC分类号： A61K31/40 , A61B5/411 , A61B5/416 , A61K41/0071 , A61N5/0601 , A61N5/062 , C07D519/00 , G02B6/262 , G02B6/4204 , A61B5/0071 , A61B5/0084 , G02B6/4298 , Y10S607/901
摘要： To provide to and receive radiation from a photodynamic drug in neoplastic tissue, a laser system transmits radiation through an interface into a radiation delivery system, which is in juxtaposition with neoplastic tissue containing a photodynamic drug. The laser system may be a single argon laser pumping a dye laser, two parallel sets of argon lasers pumping a dye laser, a krypton laser or a xenon laser. In addition to transmitting radiation from the laser to the delivery system, the interface system may: (1) direct a portion of the light back to the laser's power supply to control the intensity of the radiation emitted from the laser; and/or (2) receive light from the light conductors of the delivery system. The interface channels light to radiation sensing devices which are either from a beam splitter indicating the magnitude of the radiation delivered from the laser system to the radiation delivery system or radiation leaking through the light conductor. Luminescent light from the photodynamic drug is selected and provides an indication of drug density and in some embodiments depth of the activity.
摘要翻译：为了提供和接受来自肿瘤组织中的光动力药物的辐射，激光系统将辐射通过界面传播到放射递送系统中，辐射递送系统与包含光动力药物的肿瘤组织并置。激光系统可以是泵浦染料激光器的单个氩激光器，两个并联的氩激光器泵浦染料激光器，氪激光器或氙激光器。除了将激光发射到传送系统之外，接口系统可以：（1）将一部分光引导回激光器的电源以控制从激光器发射的辐射的强度; 和/或（2）从输送系统的光导体接收光。接口通道照射到辐射感测装置，辐射传感装置来自分束器，其指示从激光系统传送到辐射传播系统的辐射的大小或通过光导体泄漏的辐射。选择来自光动力药物的发光，并提供药物密度的指示，并且在一些实施方案中提供活动深度。

83. 发明授权

US4857314A C-reactive proteins in treatment of animal and human cancers 失效
标题翻译： C-反应蛋白治疗动物和人类癌症
公开(公告)号：US4857314A
公开(公告)日：1989-08-15
申请号：US886656
申请日：1986-07-18
申请人： Timothy E. O'Connor , Sherry L. Dupere
发明人： Timothy E. O'Connor , Sherry L. Dupere
IPC分类号： A61K38/00 , A61K38/17 , A61K38/19 , A61P35/00
CPC分类号： A61K38/191 , A61K38/1709 , Y10S514/885 , Y10S514/886
摘要： A pharmaceutical composition comprising an effective antitumor amount of a protein having tumor necrosis activity such as human tumor necrosis factor and an effective immune system stimulating amount of C-Reactive Protein to enhance the antitumor activity of the tumor necrosis factor and a method for treating tumors which comprises administering to a subject having a tumor an effective antitumor amount of a protein having tumor necrosis activity and an effective amount of C-Reactive Protein to stimulate the immune system of the subject thereby enhancing the antitumor activity of the protein.
摘要翻译：包含有效抗肿瘤量的具有肿瘤坏死活性的蛋白质如人肿瘤坏死因子和有效的免疫系统刺激量的C反应蛋白以提高肿瘤坏死因子的抗肿瘤活性的药物组合物和治疗肿瘤的方法包括向具有肿瘤的受试者施用有效抗肿瘤量的具有肿瘤坏死活性的蛋白质和有效量的C反应蛋白，以刺激受试者的免疫系统，由此增强蛋白质的抗肿瘤活性。

84. 发明授权

US4658017A Method for the large scale purification of human fibroblast interferon 失效
标题翻译：大量纯化人成纤维细胞干扰素的方法
公开(公告)号：US4658017A
公开(公告)日：1987-04-14
申请号：US579994
申请日：1984-02-14
申请人： Wlodzimierz E. Dembinski , Eugene Sulkowski
发明人： Wlodzimierz E. Dembinski , Eugene Sulkowski
IPC分类号： C07K14/565 , C07K3/20 , A61K45/02 , C07K
CPC分类号： C07K14/565 , Y10S435/811
摘要： A process for the large scale purification of human fibroblast interferon produced by human diploid fibroblasts under superinduction conditions characterized by a sequence of four chromatographic steps namely:(1) separation on CM-agarose;(2) separation on ConA-agarose;(3) separation on phenyl-agarose; and(4) elimination of ethylene glycol using CM-agarose which process yields a final overall recovery not less than 60% of the crude interferon starting material and having a specific activity not less than 1.times.10.sup.8 units per mg of protein.
摘要翻译：在超诱导条件下由人二倍体成纤维细胞产生的人成纤维细胞大规模纯化的方法，其特征在于四个色谱步骤的顺序，即：（1）在CM-琼脂糖上分离; （2）ConA琼脂糖分离; （3）苯基 - 琼脂糖分离; 和（4）使用CM-琼脂糖消除乙二醇，该方法产生不少于粗干扰素原料的60％的最终总体回收率，并且具有不小于1×10 8单位/ mg蛋白质的比活性。

85. 发明授权

US4645760A Activated aminoglycosides and aminoglycoside-aminocyclitols pharmaceutical compositions and method of use 失效
标题翻译：活性氨基糖苷类和氨基糖苷类 - 氨基环糊精的药物组合物及使用方法
公开(公告)号：US4645760A
公开(公告)日：1987-02-24
申请号：US516117
申请日：1983-07-20
申请人： Martha Pierson
发明人： Martha Pierson
IPC分类号： C12P19/54 , A61K31/70 , A61K31/7028 , A61K31/7034 , A61K31/7036 , A61P29/00 , A61P31/04 , C07H15/22 , G01N31/22 , G01N33/66 , A61K31/71 , C07H15/232
CPC分类号： G01N31/221 , C07H15/22 , G01N31/22 , Y10T436/144444
摘要： Aminoglycosides and aminoglycoside-aminocyclitols which have been oxygen-radical activated show a broad spectrum of antibacterial activity. The activated compounds are able to penetrate the cell membranes of bacteria and show substantially enhanced activity as compared to the parent unactivated compound.
摘要翻译：已经氧自由基活化的氨基糖苷类和氨基糖苷类 - 氨基二醇都显示出广谱的抗菌活性。活化的化合物能够穿透细菌的细胞膜，并且与母体未活化的化合物相比显示出显着增强的活性。

86. 发明授权

US12125206B2 In vivo magnetic resonance image distortion check apparatus and method 有权
公开(公告)号：US12125206B2
公开(公告)日：2024-10-22
申请号：US17430790
申请日：2020-02-14
申请人： Health Research, Inc.
发明人： Ismail Aldahlawi , Matthew Podgorsak , Dheerendra Prasad
IPC分类号： G06T7/00 , A61N5/10 , G06T7/60
CPC分类号： G06T7/0014 , G06T7/60 , A61N5/103 , G06T2200/04 , G06T2207/10028 , G06T2207/10088 , G06T2207/30016
摘要： An apparatus for identifying and quantifying image distortions within a patient magnetic resonance image set comprises a structure of magnetic resonance compatible materials with a high level of rigidity, where the structure is configured to cover the whole image volume of the brain region of the patient and sized to fit within a brain magnetic resonance coil when worn by a patient. A plurality of magnetic resonance fiducial markers is placed on the structure, thereby permitting the measurement of three-dimensional distances between the markers when the patient undergoes a magnetic resonance imaging procedure. Also presented is a process for identifying and quantifying image distortions within a patient magnetic resonance image set using the apparatus where the geometrical distortion is quantified and compared with a set threshold or a standard image.

87. 发明公开

US20240198127A1 LIGHT DELIVERY DEVICE AND METHOD FOR ULTRASOUND GUIDED INTERSTITIAL PHOTODYNAMIC THERAPY 审中-公开
公开(公告)号：US20240198127A1
公开(公告)日：2024-06-20
申请号：US18557950
申请日：2022-05-02
申请人： Health Research, Inc.
发明人： Sergei KURENOV , Gal SHAFIRSTEIN , Nathaniel IVANICK , David BELLNIER , Lawrence TWOREK
IPC分类号： A61N5/06
CPC分类号： A61N5/062 , A61N2005/0626 , A61N2005/063 , A61N2005/0632 , A61N2005/0659 , A61N2005/0663
摘要： A device includes a first fiber lock configured to be attached to a handle of an EUS-NA device and to selectively lock or unlock a fiber optic cable in position with respect to a sample needle. A second fiber lock is configured to be attached to abase of the EUS-NA device and to selectively lock or unlock a fiber optic cable in position. A method includes passing a fiber optic cable through a passage of the EUS-NA device such that an end of the fiber optic cable is at a tip of a sample needle of the EUS-NA device. The fiber optic cable is locked relative to the sample needle, and the sample need is advanced into the target tissue. The fiber optic cable is unlocked from the sample needle and locked relative to abase of the EUS-NA device. The sample needle is retracted such that the end of the fiber optic cable remains in the target tissue.

88. 发明授权

US11951454B2 Fluid treatment apparatus, systems, and methods 有权
公开(公告)号：US11951454B2
公开(公告)日：2024-04-09
申请号：US18249671
申请日：2021-11-22
申请人： HEALTH RESEARCH, INC.
发明人： John Paccione , David Dziewulski
IPC分类号： B01D15/02 , B01D15/20 , B01J20/34 , C02F1/28 , C02F1/32 , C02F1/36 , B01J20/08 , B01J20/10 , B01J20/20 , C02F1/70 , C02F101/30 , C02F101/34 , C02F101/36
CPC分类号： B01J20/3441 , B01D15/02 , B01D15/203 , C02F1/281 , C02F1/32 , C02F1/36 , B01J20/08 , B01J20/103 , B01J20/20 , C02F1/70 , C02F2101/301 , C02F2101/305 , C02F2101/345 , C02F2101/36 , C02F2303/16 , C02F2305/10
摘要： The present disclosure relates to a fluid treatment apparatus. The fluid treatment apparatus includes a first system for removing one or more target compounds from a fluid, said first system comprising adsorbent particles; a second system for regenerating said adsorbent particles; a first connector between said first system and said second system, said first connector configured to transfer adsorbent particles from said first system to said second system; and a second connector between said first system and said second system, said second connector configured to release of adsorbent particles from said second system, wherein said first system and said second system are decoupled. The present disclosure further relates to a system comprising one or more fluid treatment apparatus described herein. Also described herein are methods for treating fluid and a system comprising the methods for treating fluid described herein.

89. 发明公开

US20240009174A1 METHODS FOR DISRUPTING MITOCHONDRIAL UNFOLDED PROTEIN RESPONSE 审中-公开
公开(公告)号：US20240009174A1
公开(公告)日：2024-01-11
申请号：US18252024
申请日：2021-11-10
申请人： Health Research, Inc.
发明人： Dhyan CHANDRA , Rahul KUMAR , Neelu YADAV
IPC分类号： A61K31/4184 , A61P35/00
CPC分类号： A61K31/4184 , A61P35/00
摘要： The present disclosure provides methods for treating an individual in need of a composition having a compound having the following structure: Formula (I) The methods may be used to disrupt mitochondrial unfolded protein response. In various examples, a compound of the composition binds to heat shock protein 60 (HSP60) and inhibits the interaction of HSP60 to ClpP, thus interrupting the mitochondrial unfolded protein response. For example, the composition may be used as a therapeutic approach for treating advanced prostate cancers that are no longer sensitive to AR targeted therapies.

90. 发明公开

US20230210519A1 JOINTED DEVICE FOR AUTOMATIC SUTURE AND METHOD FOR SAME 审中-公开
公开(公告)号：US20230210519A1
公开(公告)日：2023-07-06
申请号：US18001001
申请日：2021-06-07
申请人： Health Research, Inc.
发明人： Khurshid GURU
IPC分类号： A61B17/04
CPC分类号： A61B17/0469 , A61B17/0467 , A61B2017/06052
摘要： A device for automatic suturing includes a shaft having a longitudinal axis. The shaft has a joint rotatable about a joint axis which is at an angle>0° to the longitudinal axis. The device includes a clamp at a distal end of the shaft. The clamp is configured to be positioned over a length of tissue to be sutured. A driver is configured to engage with a screw of the shaft so that the driver translates along a length of the shaft when the driver is rotated. A helical needle is connected to the driver such that rotation of the driver causes rotation of the helical needle. In this way, the needle is advanced or retracted over a length of the clamp and over the joint of the shaft.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式